MMP2-H

With ultrasound irradiation, M@BTO NPs can simultaneously generate reactive oxygen species (ROS) and O based on BTO mediated piezocatalysis and water splitting, significantly promoting the intratumoral infiltration of cytotoxic T lymphocytes (CTLs) and improving the PD-L1 blockade therapy to the tumor, resulting in effective tumor growth inhibition and lung metastasis suppression in a melanoma mouse model. This nanoplatform combined MMP2-activated genetic editing cell membrane with US responsive BTO for both immune stimulation and specific PD-L1 inhibition, providing a safe and robust strategy in enhancing immune response against tumor.

P1, N=36, Recruiting, City of Hope Medical Center | Trial completion date: Feb 2023 --> Dec 2023 | Trial primary completion date: Feb 2023 --> Dec 2023

This suggests that MMP2 plays a vital role in the regulation of CAFs infiltration, potentially participating in immunotherapy response, and thus representing a valuable target of immunotherapy in melanoma.

P1b, N=42, Not yet recruiting, Chimeric Therapeutics

Our findings indicate that high MMP28 expression in PAAD is associated with cancer progression, invasion, and metastasis. Hence, MMP28 might serve as an independent prognostic biomarker and a prospective therapeutic target for PAAD.

To anticipate which treatment could benefit to the bad prognostic group identified, we (i) measured an 18-gene signature (18G) predictive of the response to pembrolizumab; (ii) analyzed public single-cell transcriptomic datasets to identify the cell subsets expressing the genes associated to bad prognosis...High MMP2 can be used to select poor prognosis patients for intensified neoadjuvant or adjuvant regimens including or not immunotherapy. CAF and MMP-producing TAM targeting may be an optimal treatment strategy for MMP2 high OCSCC.

To anticipate which treatment could benefit to the bad prognostic group identified, we (i) measured an 18-gene signature (18G) predictive of the response to pembrolizumab; (ii) analyzed public single-cell transcriptomic datasets to identify the cell subsets expressing the genes associated to bad prognosis...High MMP2 can be used to select poor prognosis patients for intensified neoadjuvant or adjuvant regimens including or not immunotherapy. CAF and MMP-producing TAM targeting may be an optimal treatment strategy for MMP2 high OCSCC.

To anticipate which treatment could benefit to the bad prognostic group identified, we (i) measured an 18-gene signature (18G) predictive of the response to pembrolizumab; (ii) analyzed public single-cell transcriptomic datasets to identify the cell subsets expressing the genes associated to bad prognosis...High MMP2 can be used to select poor prognosis patients for intensified neoadjuvant or adjuvant regimens including or not immunotherapy. CAF and MMP-producing TAM targeting may be an optimal treatment strategy for MMP2 high OCSCC.

To anticipate which treatment could benefit to the bad prognostic group identified, we (i) measured an 18-gene signature (18G) predictive of the response to pembrolizumab; (ii) analyzed public single-cell transcriptomic datasets to identify the cell subsets expressing the genes associated to bad prognosis...High MMP2 can be used to select poor prognosis patients for intensified neoadjuvant or adjuvant regimens including or not immunotherapy. CAF and MMP-producing TAM targeting may be an optimal treatment strategy for MMP2 high OCSCC.

Multivariate analysis confirmed that MMP28 was an independent risk factor in PC (hazard rate = 1.308, P = .018). Our GSEA analysis found that signaling pathways including glycolysis, p53 pathway, notch signaling, estrogen response late, cholesterol homeostasis, estrogen response early, mitotic spindle, and transforming growth factor beta signaling were enriched in the group with higher MMP28 expression.High expression of MMP28 could be identified in PC, which also served as an independent risk element for PC.